Linked Life Data

12647278

Source:http://linkedlifedata.com/resource/pubmed/id/12647278

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-3-20
pubmed:abstractText
Stevioside, a glycoside present in the leaves of the plant, Stevia rebaudiana Bertoni (SrB), has acute insulinotropic effects in vitro. Its potential antihyperglycemic and blood pressure-lowering effects were examined in a long-term study in the type 2 diabetic Goto-Kakizaki (GK) rat. Rats were fed 0.025 g x kg(-1) x d(-1) of stevioside (purity > 99.6%) for 6 weeks. An intra-arterial catheter was inserted into the rats after 5 weeks, and conscious rats were subjected to arterial glucose tolerance test (2.0 g x kg(-1)) during week 6. Stevioside had an antihyperglycemic effect (incremental area under the glucose response curve [IAUC]): 985 +/- 20 (stevioside) versus 1,575 +/- 21 (control) mmol/L x 180 minutes, (P <.05), it enhanced the first-phase insulin response (IAUC: 343 +/- 33 [stevioside] v 136 +/- 24 [control] microU/mL insulin x 30 minutes, P <.05) and concomitantly suppressed the glucagon levels (total AUC: 2,026 +/- 234 [stevioside] v 3,535 +/- 282 [control] pg/mL x 180 minutes, P <.05). In addition, stevioside caused a pronounced suppression of both the systolic (135 +/- 2 v 153 +/- 5 mm Hg; P <.001) and the diastolic blood pressure (74 +/- 1 v 83 +/- 1 mm Hg; P <.001). Bolus injections of stevioside (0.025 g x kg(-1)) did not induce hypoglycemia. Stevioside augmented the insulin content in the beta-cell line, INS-1. Stevioside may increase the insulin secretion, in part, by induction of genes involved in glycolysis. It may also improve the nutrient-sensing mechanisms, increase cytosolic long-chain fatty acyl-coenzyme A (CoA), and downregulate phosphodiesterase 1 (PDE1) estimated by the microarray gene chip technology. In conclusion, stevioside enjoys a dual positive effect by acting as an antihyperglycemic and a blood pressure-lowering substance; effects that may have therapeutic potential in the treatment of type 2 diabetes and the metabolic syndrome.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0026-0495
pubmed:author
pubmed:copyrightInfo
Copyright 2003, Elsevier Science (USA). All rights reserved.
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
372-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:12647278-Animals, pubmed-meshheading:12647278-Antihypertensive Agents, pubmed-meshheading:12647278-Blood Glucose, pubmed-meshheading:12647278-Blood Pressure, pubmed-meshheading:12647278-Body Weight, pubmed-meshheading:12647278-Cell Line, pubmed-meshheading:12647278-Diabetes Mellitus, Type 2, pubmed-meshheading:12647278-Diterpenes, pubmed-meshheading:12647278-Diterpenes, Kaurane, pubmed-meshheading:12647278-Fasting, pubmed-meshheading:12647278-Gene Expression Profiling, pubmed-meshheading:12647278-Glucagon, pubmed-meshheading:12647278-Glucose Tolerance Test, pubmed-meshheading:12647278-Glucosides, pubmed-meshheading:12647278-Hypoglycemic Agents, pubmed-meshheading:12647278-Insulin, pubmed-meshheading:12647278-Islets of Langerhans, pubmed-meshheading:12647278-Kinetics, pubmed-meshheading:12647278-Male, pubmed-meshheading:12647278-Rats, pubmed-meshheading:12647278-Rats, Wistar
pubmed:year
2003
pubmed:articleTitle
Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat.
pubmed:affiliation
Department of Endocrinology and Metabolism, Molecular Diagnostic Laboratory, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't